Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03123289 · ClinicalTrials.gov registry record · Phase 2
Novel Gallium 68 Citrate in Orthopedic Infections
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03123289: Clinical Trial Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
NCT03123289 is a Phase 2 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03123289, a Phase 2 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
In the proposed study, our aim is to evaluate the uptake of 68Gallium-citrate in patients with failed joint prosthesis and compare it with that of conventional 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan. We will perform PET/CT scan with 68Gallium citrate and 18F-FDG in subjects with failed hip or knee prosthesis. Both 68Gallium-citrate and 18F-FDG scans, done within 24-48 hours from each other, will be performed within 4 weeks before surgical evaluation/revision of the hardware.
Primary Outcome
The radiotracer uptake in SUV units is measured in different Gruen zones around the prosthesis and normalized by that of the liver. The values of the two scans will be compared against each other for all patients.
Interventions
- DRUG 68-Gallium citrate PET/CT scan
- DRUG 18F FDG PET/CT scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2020-10-14 |
| Phase | Phase 2 |
Why NCT03123289 stopped before completion
NCT03123289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which 68-Gallium citrate PET/CT scan is the first listed.
NCT03123289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03123289 about?
NCT03123289 is a clinical study titled "Novel Gallium 68 Citrate in Orthopedic Infections". In the proposed study, our aim is to evaluate the uptake of 68Gallium-citrate in patients with failed joint prosthesis and compare it with that of conventional 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan. We will perform PET/CT scan with 68G...
What is the current status of trial NCT03123289?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-03-06. Estimated completion is 2020-10-14.
What interventions are being tested in trial NCT03123289?
The interventions under investigation include: 68-Gallium citrate PET/CT scan (DRUG), 18F FDG PET/CT scan (DRUG).
Who is sponsoring clinical trial NCT03123289?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03123289's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI